Search Results

You are looking at 1 - 10 of 15 items for :

  • macroprolactinoma x
  • Refine by Access: All content x
Clear All
Open access

Shruti Khare, Anurag R Lila, Hiren Patt, Chaitanya Yerawar, Manjunath Goroshi, Tushar Bandgar, and Nalini S Shah

Introduction Macroprolactinomas constitute approximately half of all the functioning pituitary macroadenomas (1) . Prolactinoma (majority being microprolactinoma) are usually diagnosed in women aged 20–50 years, with a female:male ratio of 10

Open access

Lijin Ji, Na Yi, Qi Zhang, Shuo Zhang, Xiaoxia Liu, Hongli Shi, and Bin Lu

suggest other causes for the hyperprolactinemia. Only 25 (9%) endocrinologists believed that PRL levels >250 ng/mL could occur in microadenoma, macroprolactinoma, macroprolactinemia or drug-induced hyperprolactinemia. Of the endocrinologists surveyed, 281

Open access

Ali Abbara, Sophie Clarke, Pei Chia Eng, James Milburn, Devavrata Joshi, Alexander N Comninos, Rozana Ramli, Amrish Mehta, Brynmor Jones, Florian Wernig, Ramesh Nair, Nigel Mendoza, Amir H Sam, Emma Hatfield, Karim Meeran, Waljit S Dhillo, and Niamh M Martin

remains unclear. Many reports have described spontaneous pituitary haemorrhage in prolactinomas ( 4 , 5 , 7 , 8 , 9 , 26 ). However, the rate of pituitary apoplexy in macroprolactinomas treated with dopamine agonists is reported to be 1–6%, which was

Open access

Sarah Byberg, Jesper Futtrup, Mikkel Andreassen, and Jesper Krogh

treatment vs duration of treatment of ≥6 months), percentage of included men, prolactin levels at baseline, percentage of macroprolactinoma, the effect of study design as well as the effect of risk of bias. The division of groups for subgroup analysis was

Open access

Anastasia P Athanasoulia-Kaspar, Kathrin H Popp, and Gunter Karl Stalla

disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma . Clinical Neuropharmacology 2013 36 170 – 172 . ( ) 20 Almanzar S Zapata-Vega MI Raya JA. Dopamine agonist

Open access

Debra M Gordon, Pablo Beckers, Emilie Castermans, Sebastian J C M M Neggers, Liliya Rostomyan, Vincent Bours, Patrick Petrossians, Vinciane Dideberg, Albert Beckers, and Adrian F Daly

early 20s developed acromegaly (microadenoma) FIPA (first cousin macroprolactinoma) No pathological variants on panel or MLPA  P23 F 20’s Prolactinoma (microadenoma), low bone mineral density, dysembryoplastic neuroepithelial tumor FIPA

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, and S Cannavò

In this patient, macroprolactinoma was diagnosed when she was 42 years old and trans-sphenoidal surgery was performed after few months of ineffective high-dose cabergoline treatment. At the age of 55 years, serum PRL concentrations remarkably

Open access

Fizzah Iqbal, William Adams, Ioannis Dimitropoulos, Samiul Muquit, and Daniel Flanagan

warn patients commencing dopamine agonists for treatment of macroprolactinoma that there is a risk of pituitary haemorrhage and that this can present either with a severe headache or milder symptoms. In previous studies looking at just acute

Open access

Arnaud Lagarde, Grégory Mougel, Lucie Coppin, Magalie Haissaguerre, Lauriane Le Collen, Amira Mohamed, Marc Klein, Marie-Françoise Odou, Antoine Tabarin, Hedia Brixi, Thomas Cuny, Brigitte Delemer, Anne Barlier, and Pauline Romanet

-based genetic testing, in particular in patients with multiple lesions including DPNET and thymic neuroendocrine tumor. Recently, a patient with a macroprolactinoma at 24 years of age, harboring a MEN1 mosaic variant at an AF of 11%, has been described ( 29

Open access

Ferdinand Roelfsema, Diana van Heemst, Ali Iranmanesh, Paul Takahashi, Rebecca Yang, and Johannes D Veldhuis

.1210/jc.79.6.1706 ) 26 Groote Veldman R van den Berg G Pincus SM Frolich M Veldhuis JD Roelfsema F. Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas . European Journal of